brivudine phosphoramidate
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2001 (NCT00031616)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Thymidylate synthaseINHIBITOR
TYMS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- brivudine phosphoramidate
- brivudine phosphoramidate
- nb1011
- nb1011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00248404 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2005 | Kiadis Pharma |
| NCT00031616 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2001 | NewBiotics, University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kiadis Pharma | For profit | 1 | 1 | 1 | 2005 |
| NewBiotics | For profit | 1 | 1 | 1 | 2001 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2001 |
3 organizations
Page 1 / 1